BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
February 08, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions...
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
December 11, 2023 08:00 ET
|
AiViva Biopharma
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced...
Registration Now Open for 2024 MDA Clinical & Scientific Conference, to Showcase Cutting Edge Research Advancements and Clinical Achievements in Neuromuscular Disease
August 09, 2023 10:35 ET
|
Muscular Dystrophy Association
New York, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), convener of the largest worldwide gathering of the neuromuscular disease community, announced today that...
Truveta and Alpine Immune Sciences Announce Strategic Partnership to Access Truveta’s Community to Accelerate Recruitment to Povetacicept Clinical Trials
March 22, 2023 08:45 ET
|
Truveta
BELLEVUE and SEATTLE, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Today, Truveta and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced a strategic partnership to help accelerate clinical trial...
New SDOH data in Truveta Studio provide most complete view of health equity’s influence on patient health and outcomes
March 01, 2023 09:00 ET
|
Truveta
BELLEVUE, Wash., March 01, 2023 (GLOBE NEWSWIRE) -- Truveta announced the expansion of its de-identified data to include 28 additional social drivers of health (SDOH) attributes – such as education,...
Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
July 06, 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, July 06, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI...
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
June 21, 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer...
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
February 22, 2022 07:15 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) +...
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
February 01, 2022 06:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™...
CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
December 20, 2021 10:06 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph...